Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Abstract Background Whereas there are many pharmacological interventions prescribed for patients with advanced anaplastic lymphoma kinase (ALK)- rearranged non-small cell lung cancer (NSCLC), comparative data between novel generation ALK-tyrosine kinase inhibitors (TKIs) remain scant. Here, we indir...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hao-chuan Ma, Yi-hong Liu, Kai-lin Ding, Yu-feng Liu, Wen-jie Zhao, Yan-juan Zhu, Xue-song Chang, Ya-dong Chen, Zhen-zhen Xiao, Ya-ya Yu, Rui Zhou, Hai-bo Zhang
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
ALK
Lung cancer
First-line treatment
Network meta-analysis
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/6543667632434346976330ca1a6114d6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares